title: Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies.
abstract: OBJECTIVE
  Carboplatin dosing is usually based on glomerular filtration rate (GFR). The Cockcroft-Gault and the Modified Diet in Renal Disease (MDRD) Study formulae are based on serum creatinine to estimate GFR when measured GFR is impractical. The MDRD formula has been shown to be more accurate in non-cancer patients with chronic renal disease. We compared the accuracy of these formulae for dosing carboplatin in patients with gynecological cancers.
  
  
  METHODS
  Patient data were collected retrospectively at the Vancouver Centre of the British Columbia Cancer Agency, Canada. GFR estimated by formula was compared to measured GFR. Dose derived from estimated GFR was compared to dose derived from measured GFR. Bias (percentage error) and precision (absolute percentage error) were compared with two-sided paired t-test.
  
  
  RESULTS
  A total of 96 patients were evaluable: median age 60 years, weight 62 kg, height 159 cm, baseline serum creatinine 71 micromol/l, GFR 91 ml/min. Both formulae had limited precision with a small bias for estimated GFR and dosing. Eight-five percent of patients would have received a significantly different dose if estimated GFR from any formula was used. The MDRD formula was more precise than the Cockcroft-Gault formula.
  
  
  CONCLUSIONS
  The MDRD formula seems to be more accurate than the Cockcroft-Gault formula in this population. However, both have limited precision and measured GFR should be preferred for carboplatin dosing.
authors.affiliation: Provincial Drug Information Coordinator, Provincial Systemic Therapy Program, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada. mdelemos@bccancer.bc.ca
authors.forename: Mário L
authors.initials: ML
authors.lastname: de Lemos
authors.forename: Teresa
authors.initials: T
authors.lastname: Hsieh
authors.forename: Linda
authors.initials: L
authors.lastname: Hamata
authors.forename: Adeera
authors.initials: A
authors.lastname: Levin
authors.forename: Ken
authors.initials: K
authors.lastname: Swenerton
authors.forename: Ognjenka
authors.initials: O
authors.lastname: Djurdjev
authors.forename: Thanh
authors.initials: T
authors.lastname: Vu
authors.forename: Francis
authors.initials: F
authors.lastname: Hu
authors.forename: James
authors.initials: J
authors.lastname: Conklin
authors.forename: Suzanne C
authors.initials: SC
authors.lastname: Malfair Taylor
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D019540:Area Under Curve; D015982:Bias; D001955:British Columbia; D016190:Carboplatin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D003404:Creatinine / Q000097:blood; D004334:Drug Administration Schedule; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D007668:Kidney / Q000378:metabolism; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011237:Predictive Value of Tests; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D003404:Creatinine; D016190:Carboplatin